DK1734959T3 - Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter - Google Patents
Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteterInfo
- Publication number
- DK1734959T3 DK1734959T3 DK05732721.5T DK05732721T DK1734959T3 DK 1734959 T3 DK1734959 T3 DK 1734959T3 DK 05732721 T DK05732721 T DK 05732721T DK 1734959 T3 DK1734959 T3 DK 1734959T3
- Authority
- DK
- Denmark
- Prior art keywords
- schizophrenia
- compounds
- treatment
- glucoregulatory
- abnormalities
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/011107 WO2005097122A2 (en) | 2004-04-01 | 2005-04-01 | Method of treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1734959T3 true DK1734959T3 (da) | 2010-03-08 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05732721.5T DK1734959T3 (da) | 2004-04-01 | 2005-04-01 | Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (da) |
| EP (2) | EP2138176A1 (da) |
| JP (1) | JP2007531730A (da) |
| KR (1) | KR20070010161A (da) |
| CN (1) | CN1946399A (da) |
| AR (1) | AR048197A1 (da) |
| AT (1) | ATE446754T1 (da) |
| AU (1) | AU2005231446A1 (da) |
| BR (1) | BRPI0509512A (da) |
| CA (1) | CA2561162A1 (da) |
| CL (1) | CL2009001605A1 (da) |
| CY (1) | CY1109734T1 (da) |
| DE (1) | DE602005017373D1 (da) |
| DK (1) | DK1734959T3 (da) |
| DO (1) | DOP2005000050A (da) |
| ES (1) | ES2334241T3 (da) |
| GT (1) | GT200500063A (da) |
| IL (1) | IL178168A0 (da) |
| MX (1) | MXPA06011222A (da) |
| PA (1) | PA8628601A1 (da) |
| PL (1) | PL1734959T3 (da) |
| PT (1) | PT1734959E (da) |
| SI (1) | SI1734959T1 (da) |
| SV (1) | SV2006002069A (da) |
| TW (1) | TW200602040A (da) |
| WO (1) | WO2005097122A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| US8466188B2 (en) | 2006-10-12 | 2013-06-18 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| EP2076514A1 (en) * | 2006-10-12 | 2009-07-08 | Xenon Pharmaceuticals Inc. | Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| EP2942350A1 (en) | 2008-10-17 | 2015-11-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US20100152249A1 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of The Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| AU2010256541B2 (en) * | 2009-06-03 | 2016-03-10 | Marquette University | Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| RU2015103694A (ru) | 2009-10-14 | 2015-06-27 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
| PE20121699A1 (es) | 2010-02-26 | 2012-12-22 | Xenon Pharmaceuticals Inc | Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| AR103636A1 (es) | 2015-02-05 | 2017-05-24 | Teva Pharmaceuticals Int Gmbh | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| WO2018039477A1 (en) | 2016-08-24 | 2018-03-01 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for treating functional decline |
| US11862337B2 (en) * | 2019-03-19 | 2024-01-02 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| DE3852335T2 (de) * | 1987-04-24 | 1995-05-11 | Hoechst Roussel Pharma | N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel. |
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| PT840609E (pt) * | 1995-07-27 | 2002-10-31 | Aventis Pharma Inc | Utilizacao de n-(pirrol-1-il)-pirimidinas insubstituidas e substituidas como agentes anticonvulsivos |
| BR9707003A (pt) | 1996-01-17 | 1999-07-20 | Novo Nordisk As | Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto |
| CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Application Discontinuation
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es active Active
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de active Active
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Not-in-force
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en active Application Filing
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1734959A2 (en) | 2006-12-27 |
| EP2138176A1 (en) | 2009-12-30 |
| CL2009001605A1 (es) | 2009-11-27 |
| DE602005017373D1 (de) | 2009-12-10 |
| CY1109734T1 (el) | 2014-09-10 |
| BRPI0509512A (pt) | 2007-09-11 |
| PL1734959T3 (pl) | 2010-03-31 |
| ES2334241T3 (es) | 2010-03-08 |
| IL178168A0 (en) | 2006-12-31 |
| CA2561162A1 (en) | 2005-10-20 |
| TW200602040A (en) | 2006-01-16 |
| WO2005097122A3 (en) | 2006-02-02 |
| SV2006002069A (es) | 2006-05-24 |
| US20070129403A1 (en) | 2007-06-07 |
| WO2005097122A2 (en) | 2005-10-20 |
| DOP2005000050A (es) | 2005-11-30 |
| KR20070010161A (ko) | 2007-01-22 |
| ATE446754T1 (de) | 2009-11-15 |
| GT200500063A (es) | 2005-10-14 |
| MXPA06011222A (es) | 2007-01-16 |
| PT1734959E (pt) | 2009-12-24 |
| CN1946399A (zh) | 2007-04-11 |
| PA8628601A1 (es) | 2006-05-16 |
| SI1734959T1 (sl) | 2010-02-26 |
| AR048197A1 (es) | 2006-04-05 |
| EP1734959B1 (en) | 2009-10-28 |
| AU2005231446A1 (en) | 2005-10-20 |
| JP2007531730A (ja) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1734959T3 (da) | Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter | |
| DK1771201T3 (da) | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom | |
| DK1830843T3 (da) | Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme | |
| DK1685834T3 (da) | Anvendelse af pinolensyre til behandling af obesitet | |
| DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
| DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
| DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
| DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
| DE602005027052D1 (de) | Endoskopbehandlungssystem | |
| DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK3121169T3 (da) | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser | |
| DK1720571T3 (da) | Fremgangsmåde til behandling af hæmolytisk sygdom | |
| DK2653873T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
| DK1830869T3 (da) | Fremgangsmåde til behandling eller profylakse | |
| DK2026819T3 (da) | Forebyggelse og/eller behandling af Alzheimers sygdom | |
| DE602005026825D1 (de) | Endoskop | |
| DK1750713T3 (da) | Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner | |
| DK1937633T3 (da) | Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme | |
| DK1817282T3 (da) | Til behandling af respiratoriske sygdomme egnede phenoxy derivater | |
| NO20070251A (no) | Brønnbehandling | |
| DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
| DK1863899T3 (da) | Hudbehandlingspræparater | |
| DK1835907T3 (da) | Lægemidler til behandling eller forebyggelse af fibrotiske sygdomme | |
| ZA200706113B (en) | Method for the treatment of copper-bearing materials |